Mattia Nigro

Dr. Mattia Nigro

Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2025 in European Respiratory Journal
Verified
Journal Article
Closed access
JCJames D. Chalmers
James D. Chalmers
CHCharles S. Haworth
Charles S. Haworth
PFPatrick Flume
Patrick Flume
MLMerete B. Long
Merete B. Long
PNEUMOLOGIE BurgelPNEUMOLOGIE Burgel
PNEUMOLOGIE Burgel
SAStefano Aliberti
Stefano Aliberti
Background: Bronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis. Methods: A European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of eight PICO (Patients, Intervention, Comparator, Outcomes) questions and three narrative questions were developed. Recommendations: The Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis, and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic Pseudomonas aeruginosa infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long-term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations and managing the deteriorating patient. Conclusion: The ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.

9 October 2024 in European Respiratory Review
Verified
Journal Article
Open access
PDF file
MNMattia Nigro
Mattia Nigro
ILIrena F. Laska
Irena F. Laska
LTLetizia Traversi
Letizia Traversi
ESEdoardo Simonetta
Edoardo Simonetta
EPEva Polverino
Eva Polverino
Bronchiectasis is a chronic respiratory disease characterised by permanent enlargement of the airways associated with cough, sputum production and a history of pulmonary exacerbations. In the past few years, incidence and prevalence of bronchiectasis have increased worldwide, possibly due to advances in imaging techniques and disease awareness, leading to increased socioeconomic burden and healthcare costs. Consistently, a mortality increase in bronchiectasis patient cohorts has been demonstrated in certain areas of the globe, with mortality rates of 16–24.8% over 4–5 years of follow-up. However, heterogeneity in epidemiological data is consistent, as reported prevalence in the general population ranges from 52.3 to more than 1000 per 100 000. Methodological flaws in the designs of available studies are likely to underestimate the proportion of people suffering from this condition worldwide and comparisons between different areas of the globe might be unreliable due to different assessment methods or local implementation of the same method in different contexts. Differences in disease severity associated with diverse geographical distribution of aetiologies, comorbidities and microbiology might explain an additional quota of heterogeneity. Finally, limited access to care in certain geographical areas is associated with both underestimation of the disease and increased severity and mortality. The aim of this review is to provide a snapshot of available real-world epidemiological data describing incidence and prevalence of bronchiectasis in the general population. Furthermore, data on mortality, healthcare burden and high-risk populations are provided. Finally, an analysis of the geographical distribution of determinants contributing to differences in bronchiectasis epidemiology is offered.

9 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Claudia CrimiClaudia Crimi
Claudia Crimi
Santi NolascoSanti Nolasco
Santi Nolasco
Raffaele CampisiRaffaele Campisi
Raffaele Campisi
MNMattia Nigro
Mattia Nigro
PIPietro Impellizzeri
Pietro Impellizzeri
ACAnnalisa Carlucci
Annalisa Carlucci
High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE). Methods: This is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary function were collected. The primary outcome was the change from baseline in the exacerbation rates at 12 months between groups. Results: 20 patients in the HFNT group and 20 controls were included. A significant reduction in exacerbations [−1.9 (−2.8 to −0.9), p = 0.0005] and hospitalizations [−0.7 (−1.1 to −0.3), p = 0.0006] was found in the HFNT group vs controls. A slight improvement in pulmonary function [FEV1% +6,1% (+1% to +11.3%) (p = 0.0219), FVC% +4.6% (+0.8% to +8.3%) (p = 0.0188) and FEF25–75% +13.4 (+11 to +15.9) (p = 0.0189) was also found in the HFNT group compared to controls. Conclusions: In this preliminary study, long-term domiciliary HFNT improved the clinical course of patients with BE.

1 July 2025 in European Respiratory Review
Verified
Journal Article
Open access
AAAlessandro De Angelis
Alessandro De Angelis
MMMartina Marchello
Martina Marchello
ATAngela Tramontano
Angela Tramontano
MCMarianna Cicchetti
Marianna Cicchetti
MNMattia Nigro
Mattia Nigro
SAStefano Aliberti
Stefano Aliberti
Bronchiectasis is a chronic respiratory disease characterised by irreversible bronchial dilation, persistent productive cough and alternating periods of clinical stability and exacerbations. The distorted airways impair mucus clearance, making them susceptible to recurrent infections and chronic inflammation. Haemophilus influenzae is a common pathogen in bronchiectasis according to international registries. It employs several virulence mechanisms, including adhesion, intracellular invasion/survival, biofilm formation and evasion of antibiotic treatments, to establish infection. These mechanisms allow H. influenzae to persist in the respiratory tract and evade host immune defences. Although its role is well-documented in other airway diseases, the impact of H. influenzae in bronchiectasis remains incompletely understood. International guidelines do not recommend eradication therapy for H. influenzae upon first isolation, while this intervention is advised for Pseudomonas aeruginosa in such cases. Long-term immunomodulatory treatment with macrolides is an option for patients with bronchiectasis with chronic H. influenzae infection and frequent exacerbations, though it carries the risk of promoting antibiotic resistance and a Pseudomonas-enriched airway microbiome. Studies indicate significant negative interactions between P. aeruginosa and H. influenzae, suggesting a competitive relationship that can influence microbiome dynamics and potentially affect clinical outcomes. Currently, there is insufficient evidence to support vaccination against nontypeable H. influenzae in chronic airways disease. Despite its frequent detection in respiratory samples, the precise role of H. influenzae in bronchiectasis-related morbidity and disease progression is not fully understood and warrants further investigation. This review examines the impact of H. influenzae on bronchiectasis pathophysiology and progression, comparing its role in other chronic respiratory diseases.

Verified
Journal Article
Open access
PDF file
FAFrancesco Amati
Francesco Amati
FBFrancesco Bindo
Francesco Bindo
ASAnna Stainer
Anna Stainer
AGAndrea Gramegna
Andrea Gramegna
MMMarco Mantero
Marco Mantero
SAStefano Aliberti
Stefano Aliberti
A substantial increase in broad-spectrum antibiotics as empirical therapy in patients with community-acquired pneumonia (CAP) has occurred over the last 15 years. One of the driving factors leading to that has been some evidence showing an increased incidence of drug-resistant pathogens (DRP) in patients from a community with pneumonia, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Research has been published attempting to identify DRP in CAP through the implementation of probabilistic approaches in clinical practice. However, recent epidemiological data showed that the incidence of DRP in CAP varies significantly according to local ecology, healthcare systems and countries where the studies were performed. Several studies also questioned whether broad-spectrum antibiotic coverage might improve outcomes in CAP, as it is widely documented that broad-spectrum antibiotics overuse is associated with increased costs, length of hospital stay, drug adverse events and resistance. The aim of this review is to analyze the different approaches used to identify DRP in CAP patients as well as the outcomes and adverse events in patients undergoing broad-spectrum antibiotics.

8 May 2025 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
MNMattia Nigro
Mattia Nigro
AAAndrea Aliverti
Andrea Aliverti
AAAlessandra Angelucci
Alessandra Angelucci
FBFulvio Braido
Fulvio Braido
GCGiorgio W. Canonica
Giorgio W. Canonica
SAStefano Aliberti
Stefano Aliberti